Get started
Author

Tomohide Tamura

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
2011 · Kazuhiko Yamada, Noboru Yamamoto, et al. · Clinical Cancer Research · 162
PDF
AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor
2007 · Masayuki Takeda, Tokuzo Arao, et al. · Clinical Cancer Research · 136
mTOR Signal and Hypoxia-Inducible Factor-1α Regulate CD133 Expression in Cancer Cells
2009 · Kazuko Matsumoto, Tokuzo Arao, et al. · Cancer Research · 134
Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility.
2002 · Noriaki Sunaga, Takashi Kohno, et al. · PubMed · 127
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
2015 · Yutaka Fujiwara, Hiroshi Nokihara, et al. · Cancer Chemotherapy and Pharmacology · 101
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients
2009 · Kimie Sai, Yoshiro Saito, et al. · Cancer Chemotherapy and Pharmacology · 60
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients
2010 · Kimie Sai, Yoshiro Saito, et al. · British Journal of Clinical Pharmacology · 51
PDF
Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells
2001 · Kazuto Nishio, Takashi Nakamura, et al. · Cancer · 51
PDF
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
2009 · Noboru Yamamoto, Noboru Yamamoto, et al. · Cancer Chemotherapy and Pharmacology · 47
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
2009 · Yutaka Fujiwara, Noboru Yamamoto, et al. · Cancer Science · 41
PDF
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
2012 · Hajime Asahina, Hiroshi Nokihara, et al. · Investigational New Drugs · 37
P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors
2003 · Catherine Wheeler, Hironobu Minami, et al. · Lung Cancer · 33
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors
2013 · Kazunori Honda, Noboru Yamamoto, et al. · Cancer Chemotherapy and Pharmacology · 29
Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines
2014 · Yasufumi Katanasaka, Yasuo Kodera, et al. · Cancer Letters · 28
Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese
2008 · Yoshiro Saito, Kimie Sai, et al. · Drug Metabolism and Disposition · 27
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells
2015 · Takeshi Sawada, Masaru Watanabe, et al. · Cancer Science · 25
PDF
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
2012 · Hajime Asahina, Yosuke Tamura, et al. · Cancer Chemotherapy and Pharmacology · 23
PDF
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
2011 · Yoshitaka Seki, Noboru Yamamoto, et al. · Cancer Chemotherapy and Pharmacology · 23
PDF
A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro
1992 · Huaiyuan Jiao, Weiming Shen, et al. · Cancer Immunology Immunotherapy · 23
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients
2007 · Kimie Sai, Yoshiro Saito, et al. · Cancer Chemotherapy and Pharmacology · 22
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
2010 · Yasuhito Fujisaka, Yasuhide Yamada, et al. · Cancer Chemotherapy and Pharmacology · 21
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors
2005 · Yasuhide Yamada, Tomohide Tamura, et al. · Cancer Chemotherapy and Pharmacology · 20
Preliminary Evaluation of the New Tumor Marker, CYFRA 21-1, in Lung Cancer Patients
1994 · Hironori Koga, Kenji Eguchi, et al. · Japanese Journal of Clinical Oncology · 20
A phase I study of resminostat in Japanese patients with advanced solid tumors
2015 · Satoru Kitazono, Yutaka Fujiwara, et al. · Cancer Chemotherapy and Pharmacology · 18
Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study
2001 · Hirotaka Takama, Hideji Tanaka, et al. · Cancer Chemotherapy and Pharmacology · 18
Works count: 58
Citation count: 1,476
H-index: 21
I10-index: 35
Year
Topic
Type